Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02822599 · ClinicalTrials.gov registry record · Phase 4
Human Fibrinogen Concentrate in Pediatric Cardiac Surgery
A Phase 4 study, sponsored by Nicklaus Children's Hospital f/k/a Miami Children's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT02822599 is a Phase 4 study that has completed, run by Nicklaus Children's Hospital f/k/a Miami Children's Hospital. The registered enrollment target is 30 participants.
The verdict
NCT02822599, a Phase 4 study, has completed, sponsored by Nicklaus Children's Hospital f/k/a Miami Children's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The goal of the study is to determine whether the use of Human Fibrinogen Concentrate (RiaSTAP) will decrease blood loss and the need for component blood therapy in neonates and infants undergoing cardiopulmonary bypass.
Interventions
- DRUG Saline
- DRUG RiaStAP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2020-12-24 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02822599
The ClinicalTrials.gov registry entry for NCT02822599 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nicklaus Children's Hospital f/k/a Miami Children's Hospital, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT02822599 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02822599 about?
NCT02822599 is a clinical study titled "Human Fibrinogen Concentrate in Pediatric Cardiac Surgery". The goal of the study is to determine whether the use of Human Fibrinogen Concentrate (RiaSTAP) will decrease blood loss and the need for component blood therapy in neonates and infants undergoing cardiopulmonary bypass.
What is the current status of trial NCT02822599?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2017-06-01. Estimated completion is 2020-12-24.
What interventions are being tested in trial NCT02822599?
The interventions under investigation include: Saline (DRUG), RiaStAP (DRUG).
Who is sponsoring clinical trial NCT02822599?
This trial is sponsored by Nicklaus Children's Hospital f/k/a Miami Children's Hospital, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.